Milestone Pharmaceuticals Analyst Ratings
Milestone Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 706.45% | HC Wainwright & Co. | $25 → $25 | Reiterates | Buy → Buy |
| 06/20/2023 | 29.03% | Jefferies | $8 → $4 | Downgrades | Buy → Hold |
| 05/23/2023 | 706.45% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/15/2023 | 706.45% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 04/12/2023 | 319.35% | Oppenheimer | $16 → $13 | Maintains | Outperform |
| 03/30/2023 | 706.45% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 03/09/2023 | 706.45% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 11/14/2022 | 706.45% | HC Wainwright & Co. | $20 → $25 | Maintains | Buy |
| 04/22/2022 | 222.58% | Piper Sandler | $8 → $10 | Upgrades | Neutral → Overweight |
| 03/05/2021 | 545.16% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
| 07/29/2020 | 480.65% | Oppenheimer | → $18 | Upgrades | Perform → Outperform |
| 07/24/2020 | 383.87% | Jefferies | $3 → $15 | Upgrades | Hold → Buy |
| 03/25/2020 | — | Jefferies | Downgrades | Buy → Hold | |
| 03/24/2020 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/24/2020 | -3.23% | Piper Sandler | → $3 | Downgrades | Overweight → Neutral |
| 06/03/2019 | 803.23% | Jefferies | → $28 | Initiates Coverage On | → Buy |
| 06/03/2019 | 754.84% | Piper Sandler | → $26.5 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 706.45% | HC Wainwright公司 | $25→$25 | 重申 | 購買→購買 |
| 06/20/2023 | 29.03% | 傑富瑞 | $8→$4 | 評級下調 | 購買→Hold |
| 2023年05月23日 | 706.45% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 2023年05月15日 | 706.45% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 04/12/2023 | 319.35% | 奧本海默 | $16→$13 | 維護 | 跑贏大盤 |
| 03/30/2023 | 706.45% | HC Wainwright公司 | →$25 | 重申 | →購買 |
| 03/09/2023 | 706.45% | HC Wainwright公司 | →$25 | 重申 | →購買 |
| 2022年11月14日 | 706.45% | HC Wainwright公司 | $20→$25 | 維護 | 買 |
| 04/22/2022 | 222.58% | 派珀·桑德勒 | $8→$10 | 升級 | 中性→超重 |
| 03/05/2021 | 545.16% | HC Wainwright公司 | →$20 | 開始承保 | →購買 |
| 07/29/2020 | 480.65% | 奧本海默 | →$18 | 升級 | →表現強於大盤 |
| 07/24/2020 | 383.87% | 傑富瑞 | $3→$15 | 升級 | 持有→購買 |
| 03/25/2020 | - | 傑富瑞 | 評級下調 | 購買→Hold | |
| 03/24/2020 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 03/24/2020 | -3.23% | 派珀·桑德勒 | →$3 | 評級下調 | 超重→中性 |
| 2019年03月06日 | 803.23% | 傑富瑞 | →$28 | 開始承保 | →購買 |
| 2019年03月06日 | 754.84% | 派珀·桑德勒 | →$26.5 | 開始承保 | →超重 |
What is the target price for Milestone Pharmaceuticals (MIST)?
里程碑製藥(MIST)的目標價是多少？
The latest price target for Milestone Pharmaceuticals (NASDAQ: MIST) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $25.00 expecting MIST to rise to within 12 months (a possible 706.45% upside). 8 analyst firms have reported ratings in the last year.
邁爾斯頓製藥公司(納斯達克代碼：MIST)的最新目標價是由HC Wainwright&Co.於2023年8月14日報道的。這家分析公司將目標價定為25美元，預計Mist將在12個月內升至(可能上漲706.45%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Milestone Pharmaceuticals (MIST)?
邁爾斯頓製藥(MIST)的最新分析師評級是多少？
The latest analyst rating for Milestone Pharmaceuticals (NASDAQ: MIST) was provided by HC Wainwright & Co., and Milestone Pharmaceuticals reiterated their buy rating.
分析師對邁爾斯頓製藥公司(納斯達克代碼：MIST)的最新評級由HC Wainwright&Co.提供，邁爾斯頓製藥公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Milestone Pharmaceuticals (MIST)?
里程碑製藥(MIST)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Milestone Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Milestone Pharmaceuticals was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與里程碑製藥的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。里程碑製藥的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右的某個時候公佈。
Is the Analyst Rating Milestone Pharmaceuticals (MIST) correct?
分析師評級里程碑製藥(MIST)正確嗎？
While ratings are subjective and will change, the latest Milestone Pharmaceuticals (MIST) rating was a reiterated with a price target of $25.00 to $25.00. The current price Milestone Pharmaceuticals (MIST) is trading at is $3.10, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的里程碑製藥(MIST)評級被重申，目標價在25.00美元至25.00美元之間。目前，里程碑製藥(MIST)的交易價格為3.10美元，超出了分析師的預測區間。